- Report
- March 2024
- 182 Pages
Global
From €3251EUR$3,374USD£2,797GBP
€3612EUR$3,749USD£3,107GBP
- Report
- January 2024
- 200 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- May 2024
- 196 Pages
Global
From €4770EUR$4,950USD£4,103GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1445EUR$1,500USD£1,243GBP
- Report
- April 2023
- 114 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Report
- January 2022
- 105 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Report
- August 2022
- 78 Pages
Global
From €3806EUR$3,950USD£3,274GBP
- Report
- August 2022
- 157 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Report
- May 2023
- 99 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- September 2019
Global
From €5174EUR$5,370USD£4,451GBP
The Anti Rejection Drug market is a subset of the Immunosuppressive Drug market, which is used to prevent the body from rejecting transplanted organs. These drugs are used to suppress the immune system, allowing the body to accept the transplanted organ. The drugs are typically used in combination with other drugs, such as corticosteroids, to reduce the risk of organ rejection. The drugs are also used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
The Anti Rejection Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Novartis, Pfizer, Merck, Bristol-Myers Squibb, and AstraZeneca. Other companies in the market include AbbVie, Sanofi, GlaxoSmithKline, and Johnson & Johnson. Show Less Read more
